Marginal Zone Lymphoma (MZL)
Also known as: MZL / Marginal Zone Lymphomas / Marginal Lymphoma / Lymphoma, Marginal Zone / Marginal Zone Lymphoma / Marginal zone B-cell lymphoma (morphologic abnormality) / Marginal zone lymphoma (disorder) / Primary cutaneous marginal zone B-cell lymphoma (disorder) / Primary cutaneous marginal zone B-cell lymphoma (morphologic abnormality) / Bronchus-associated lymphoid tissue lymphoma / BALT lymphoma / Small cell B-cell lymphoma / Nodal marginal zone B-cell lymphoma (disorder) / Nodal marginal zone B-cell lymphoma / Monocytoid B-cell lymphoma (disorder) / Nodal marginal zone B-cell lymphomas / Nodal marginal zone B-cell lymphoma NOS / Nodal marginal zone B-cell lymphoma (morphologic abnormality) / Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] / Lymphoma, B-Cell, Marginal Zone / MALT lymphoma / Mucosa-associated lymphoma (disorder) / Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (disorder) / Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (morphologic abnormality)
Drug | Drug Name | Drug Description |
---|---|---|
DB09053 | Ibrutinib | An antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia. |
DB00480 | Lenalidomide | A thalidomide derivative used to treat multiple myeloma and anemia in low to intermediate risk myelodysplastic syndrome. |
DB15035 | Zanubrutinib | A kinase inhibitor used to treat mantle cell lymphoma, a type of B-cell non-Hodgkin lymphoma, in adults who previously received therapy. |